EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses

Lakshmi Venkata Simhachalam Kutikuppala iD, Islam Kourampi iD, Ramya S D Kanagala iD, Priyadarshini Bhattacharjee iD, Sri Harsha Boppana

Medical Sciences · 22.05.2024 · 12 (2) · 28

DOI: 10.3390/medsci12020028 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Sciences, online erschienen am 22.05.2024. Verfasst von Lakshmi Venkata Simhachalam Kutikuppala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Dr. YSR University of Health Sciences, Vijayawada 520008, India. Hauptthemen laut MEDLINE: mRNA Vaccines, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mRNA vaccines have emerged as an optimistic technological platform for vaccine innovation in this new scientific era. mRNA vaccines have dramatically altered the domain of vaccinology by offering a versatile and rapid approach to combating infectious diseases and virus-induced cancers. Clinical trials have demonstrated efficacy rates of 94–95% in preventing COVID-19, and mRNA vaccines have been increasingly recognized as a powerful vaccine platform. Although mRNA vaccines have played an essential role in the COVID-19 pandemic, they still have several limitations; their instability and degradation affect their storage, delivery, and over-all efficiency. mRNA is typically enclosed in a transport mechanism to facilitate its entry into the target cell because it is an unstable and negatively charged molecule. For instance, mRNA that is given using lipid-nanoparticle-based vaccine delivery systems (LNPs) solely enters cells through endocytosis, establishing an endosome without damaging the cell membrane. The COVID-19 pandemic has accelerated the development of mRNA vaccine platforms used to treat and prevent several infectious diseases. This technology has the potential to change the future course of the disease by providing a safe and effective way to combat infectious diseases and cancer. A single-stranded genetic sequence found in mRNA vaccines instructs host cells to produce proteins inside ribosomes to elicit immunological responses and prepare the immune system to fight infections or cancer cells. The potential applications of mRNA vaccine technology are vast and can lead to the development of a preferred vaccine pattern. As a result, a new generation of vaccinations has gradually gained popularity and access to the general population. To adapt the design of an antigen, and even combine sequences from different variations in response to new changes in the viral genome, mRNA vaccines may be used. Current mRNA vaccines provide adequate safety and protection, but the duration of that protection can only be determined if further clinical research is conducted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

mRNA VaccinesCOVID-19SARS-CoV-2HumansPandemicsOncogenic VirusesVaccines, SyntheticVaccine DevelopmentCOVID-19 VaccinesViral VaccinesRNA, MessengerNeoplasms

Stichwörter der Autor:innen

infectious diseasesmRNA technologyvaccine researchvirus induced cancers

Substanzen

mRNA VaccinesVaccines, SyntheticCOVID-19 VaccinesViral VaccinesRNA, Messenger

Autor:innen und Institutionen

  • Department of General Surgery, Dr. YSR University of Health Sciences, Vijayawada 520008, India.
  • Department of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Medicine, Dr. KNR University of Health Sciences, Warangal 506007, India.
  • Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.
  • Department of Anesthesia and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA.

ORCID-Profile: Lakshmi Venkata Simhachalam Kutikuppala, Islam Kourampi, Ramya S D Kanagala, Priyadarshini Bhattacharjee

Zitieren

APA

Kutikuppala, L. V. S., Kourampi, I., Kanagala, R. S. D., Bhattacharjee, P., & Boppana, S. H. (2024). Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses. Medical Sciences, 12(2), 28. https://doi.org/10.3390/medsci12020028

Vancouver

Kutikuppala LVS, Kourampi I, Kanagala RSD, Bhattacharjee P, Boppana SH. Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses. Medical Sciences. 2024;12(2):28. doi:10.3390/medsci12020028

BibTeX
@article{Kutikuppala2024,
  author = {Kutikuppala, Lakshmi Venkata Simhachalam and Kourampi, Islam and Kanagala, Ramya S D and Bhattacharjee, Priyadarshini and Boppana, Sri Harsha},
  title = {Prospects and Challenges in Developing mRNA Vaccines for Infectious Diseases and Oncogenic Viruses},
  journal = {Medical Sciences},
  year = {2024},
  volume = {12},
  number = {2},
  pages = {28},
  doi = {10.3390/medsci12020028}
}
Kostenlos starten →